Further advancements for the reliable detection of genomic alterations leading to ALK inhibitor resistance from the peripheral blood via liquid biopsies analyzing cell-free DNA fragments (cfDNA)/circulating tumor DNA (ctDNA) are urgently warranted for optimal treatment guidance. The gene discussed is ALK; the disease is neoplasm.